Covered recipient · General Payments record
LAURENCE H BELKOFF
Allopathic & Osteopathic Physicians Urology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$6,894.67
108 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $3,230.17 | 104 |
| Consulting Fee | $3,220.00 | 1 |
| Travel and Lodging | $359.50 | 2 |
| Education | $85.00 | 1 |
By paying entity
PY2022 · entire year · sorted by reported total
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LAURENCE H BELKOFF
NPI 1689679938 · CMS profile ID 258352
Allopathic & Osteopathic Physicians / Urology
BALA CYNWYD, PA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LAURENCE H BELKOFF, NPI 1689679938, CMS profile ID 258352, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–108 of 108 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1689679938?year=2022&recipient=provider&page=3#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
108 matching records · $6,894.67 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 101–108 of 108.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $20.99 | 02/08/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940118133 | CMS |
| ABBVIE INC. | $11.46 | 02/05/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 890587965 | CMS |
| PFIZER INC. | $14.23 | 02/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 949131927 | CMS |
| UROVANT SCIENCES INC | $17.35 | 01/21/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 931054127 | CMS |
| Sun Pharmaceutical Industries Inc. | $23.78 | 01/20/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 947823599 | CMS |
| UroGen Pharma, Inc. | $23.80 | 01/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 907970929 | CMS |
| Myovant Sciences Inc. | $15.83 | 01/14/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 941179763 | CMS |
| Astellas Pharma US Inc | $85.00 | 01/05/2022 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 940096015 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $9,626.00 | 1 |
| PY2025 | Principal investigator | $2,361,417.34 | 207 |
| PY2024 | Principal investigator | $3,029,808.39 | 208 |
| PY2023 | Principal investigator | $2,730,616.25 | 244 |
| PY2022 | Principal investigator | $4,084,891.54 | 189 |
| PY2021 | Principal investigator | $2,950,941.30 | 132 |
| PY2020 | Principal investigator | $2,563,048.00 | 292 |
| PY2019 | Principal investigator | $895,863.11 | 222 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
208 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Merck Sharp & Dohme LLC | $10,129.43 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232925151 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $49,555.33 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926787 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $180,022.93 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926789 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $12,322.38 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927525 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $38,620.21 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 | No dispute reported | 06/30/2026 | 1232927539 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $16,731.35 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232928025 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $20,482.77 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Treatment with One Next generation Hor | No dispute reported | 06/30/2026 | 1232930203 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $11,014.20 | 12/31/2025 | Non-covered Recipient Entity MidLantic urology | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935105 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $193,571.57 | 12/29/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bacillus Calmette- Guerin BCG in Participants with High-risk Non-muscle Invasive Bladder Cancer HR NMIBC that i | No dispute reported | 06/30/2026 | 1232926785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 12/26/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378838 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,766.00 | 12/25/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175378759 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 12/24/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228740725 |
| Principal investigator 1 | Janssen Research & Development, LLC | $115.00 | 12/22/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264399 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,700.00 | 12/22/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264444 |
| Principal investigator 1 | Janssen Research & Development, LLC | $88.00 | 12/22/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264512 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,950.00 | 12/22/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175379103 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $3,156.00 | 12/22/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657727 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $5,620.00 | 12/22/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176657735 |
| Principal investigator 1 | Janssen Research & Development, LLC | $898.00 | 12/18/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175378861 |
| Principal investigator 1 | Janssen Research & Development, LLC | $27,462.00 | 12/18/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Follow-up of PSMA-PET-Negative Patients | No dispute reported | 06/30/2026 | 1175379139 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,222.00 | 12/15/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378900 |
| Principal investigator 1 | AstraZeneca UK Limited | $12,980.00 | 12/05/2025 | Non-covered Recipient Entity MIDLANTIC UROLOGY LLC | A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) | No dispute reported | 06/30/2026 | 1185543192 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $65,170.00 | 12/03/2025 | Non-covered Recipient Entity MidLantic urology | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935103 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,860.00 | 12/01/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379065 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,338.00 | 11/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175378938 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $120.18 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409566 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409576 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $77.50 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409580 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,980.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409582 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409620 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $210.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409622 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $96.81 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409630 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409642 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $210.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409654 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $96.81 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409670 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $77.50 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409680 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $163.58 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409690 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409700 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $51.19 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409702 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $51.19 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409708 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $120.18 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409720 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409724 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409752 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $163.58 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409762 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $99.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409764 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $51.19 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409776 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $210.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409788 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $120.18 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409790 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409796 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $163.58 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409814 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $210.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409816 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $77.50 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409820 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $99.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409830 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $96.81 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409836 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $715.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409840 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $715.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409842 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,018.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409856 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $99.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409874 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409890 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 11/27/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409906 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,165.00 | 11/27/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175378947 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,173.00 | 11/24/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264383 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,466.00 | 11/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175378793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,116.40 | 11/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175379018 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 11/21/2025 | Non-covered Recipient Entity Urologic Consultants Of Southeastern Pennsylvania Admn | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175264427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,897.00 | 11/21/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-muscle-invasive Bladder Cancer (HR-NMIBC) and Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175379082 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,632.00 | 11/18/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175378909 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $14,686.00 | 11/17/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991 | No dispute reported | 06/30/2026 | 1232927355 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,918.00 | 11/14/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264486 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,132.00 | 11/07/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379177 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,384.00 | 11/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175379187 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,765.00 | 11/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175379195 |
| Principal investigator 1 | Janssen Research & Development, LLC | $450.05 | 10/27/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378876 |
| Principal investigator 1 | Janssen Research & Development, LLC | $47,000.00 | 10/17/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175378882 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,334.82 | 10/15/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225410286 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,440.00 | 10/13/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175378830 |
| Principal investigator 1 | Janssen Research & Development, LLC | $158.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264365 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,704.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264374 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,327.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264436 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,982.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264466 |
| Principal investigator 1 | Janssen Research & Development, LLC | $426.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264493 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,370.00 | 10/07/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264549 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,066.00 | 10/06/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378846 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,270.00 | 10/06/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | MoonRISe-1 - A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations | No dispute reported | 06/30/2026 | 1175379050 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,096.00 | 10/02/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175264504 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,171.00 | 10/02/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) | No dispute reported | 06/30/2026 | 1175379147 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,123.00 | 09/29/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264405 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $34,287.60 | 09/29/2025 | Non-covered Recipient Entity MidLantic urology | A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab MK-3475 Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer KEYNOTE-B15 , EV-304 | No dispute reported | 06/30/2026 | 1232927537 |
| Principal investigator 1 | Janssen Research & Development, LLC | $15,734.40 | 09/26/2025 | Non-covered Recipient Entity Urologic Consultants | A Multi Center Randomized Double Blind Placebo Controlled Phase III Study of ARN509 in Men With Non Metastatic M0 Castration Resistant Prostate Cancer | No dispute reported | 06/30/2026 | 1175264419 |
| Principal investigator 1 | Janssen Research & Development, LLC | $540.00 | 09/26/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175379209 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $3,650.00 | 09/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892474 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,100.00 | 09/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247892477 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $4,190.00 | 09/22/2025 | Non-covered Recipient Entity MidLantic urology | A Phase III, Randomized, Double-blind, Matching Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 in Combination With Chemoradiotherapy CRT versus CRT Alone in Participants with Muscle-invasive Bladder Cancer | No dispute reported | 06/30/2026 | 1232928023 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $550.00 | 09/11/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) | No dispute reported | 06/30/2026 | 1242060987 |
| Principal investigator 1 | Janssen Research & Development, LLC | $983.00 | 09/08/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379090 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $149,672.64 | 08/31/2025 | Non-covered Recipient Entity MidLantic urology | A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph | No dispute reported | 06/30/2026 | 1232935329 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,044.00 | 08/28/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264351 |
| Principal investigator 1 | Ferring Pharmaceuticals AS | $21,772.00 | 08/27/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 2, Randomised, Multi-center, Open Label Trial to Evaluate the Safety and Efficacy of Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade Bacillus Calmette-Guerin Therapy (BCG) Unresponsive Non-muscle Invasive Bladder Cancer (NMIBC) | No dispute reported | 06/30/2026 | 1242060874 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,665.05 | 08/25/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378809 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,918.00 | 08/18/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264575 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 08/18/2025 | Non-covered Recipient Entity Urologic Consultants Of Southeastern Pennsylvania Admn | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175264591 |
| Principal investigator 1 | Janssen Research & Development, LLC | $771.00 | 08/18/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175379111 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 07/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,225.00 | 07/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175378961 |
| Principal investigator 1 | Janssen Research & Development, LLC | $139.05 | 07/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175379096 |
| Principal investigator 1 | Janssen Research & Development, LLC | $28,465.00 | 07/18/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264479 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,721.00 | 07/18/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264544 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,334.82 | 07/14/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225409106 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $502,463.00 | 07/11/2025 | Non-covered Recipient Entity MIDLANTIC UROLOGY LLC | A Randomized 2-cohort Double-blind Placebo-controlled Phase III Study of AZD5305 in Combination with Physicians Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer EvoPAR-Prostate01 | No dispute reported | 06/30/2026 | 1185543188 |
| Principal investigator 1 | Janssen Research & Development, LLC | $173.00 | 07/07/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,192.00 | 07/04/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175264391 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,700.00 | 07/04/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175264413 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,285.00 | 07/04/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle invasive Bladder Cancer MIBC of the Bladder | No dispute reported | 06/30/2026 | 1175264536 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,306.00 | 07/04/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175378976 |
| Principal investigator 1 | Janssen Research & Development, LLC | $311.00 | 06/30/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175379074 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,758.00 | 06/27/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175378998 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $1,500.00 | 06/13/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227680032 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $750.00 | 06/13/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227680414 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $1,500.00 | 06/13/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227680787 |
| Principal investigator 1 | COLOPLAST CORP | $7,895.00 | 06/11/2025 | Non-covered Recipient Entity Centers for Advanced Urology LLP | INTIBIA | No dispute reported | 06/30/2026 | 1226927370 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,136.00 | 06/09/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264357 |
| Principal investigator 1 | Janssen Research & Development, LLC | $20,165.00 | 06/09/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378814 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,002.00 | 06/06/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Ca | No dispute reported | 06/30/2026 | 1175378983 |
| Recipient | Dendreon Pharmaceuticals LLC | $9,626.00 | 06/05/2025 | Covered Recipient Physician | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891294 |
| Principal investigator 2 | Dendreon Pharmaceuticals LLC | $9,626.00 | 06/05/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY | ProvONE | No dispute reported | 06/30/2026 | 1247892160 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,334.82 | 06/04/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned | No dispute reported | 06/30/2026 | 1225408128 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,352.75 | 06/02/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378916 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 06/02/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790884 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 06/02/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792749 |
| Principal investigator 1 | Janssen Research & Development, LLC | $449.00 | 05/29/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175378785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $18,141.00 | 05/19/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378991 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,494.00 | 05/19/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379034 |
| Principal investigator 1 | Janssen Research & Development, LLC | $16,291.00 | 05/19/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379217 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,918.00 | 05/16/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264557 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,264.00 | 05/12/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379158 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 05/09/2025 | Non-covered Recipient Entity Urologic Consultants Of Southeastern Pennsylvania | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175264568 |
| Principal investigator 1 | COLOPLAST CORP | $5,040.23 | 05/06/2025 | Non-covered Recipient Entity Centers for Advanced Urology LLP | INTIBIA | No dispute reported | 06/30/2026 | 1226927372 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 05/05/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228723046 |
| Principal investigator 1 | MEDIVATION LLC. | $564.20 | 05/05/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228790227 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 05/05/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228792903 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,354.00 | 05/01/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175379119 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,255.45 | 04/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378768 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 04/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378822 |
| Principal investigator 1 | Janssen Research & Development, LLC | $779.00 | 04/28/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175379011 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,716.00 | 04/24/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264474 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,060.00 | 04/11/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,955.00 | 04/07/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175378777 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,340.00 | 04/07/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379043 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,416.00 | 04/04/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264528 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,033.00 | 04/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175378931 |
| Principal investigator 1 | Janssen Research & Development, LLC | $771.00 | 03/31/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175379132 |
| Principal investigator 1 | Janssen Research & Development, LLC | $902.70 | 03/27/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378924 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,334.82 | 03/24/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225402919 |
| Principal investigator 1 | Janssen Research & Development, LLC | $10,802.00 | 03/17/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264520 |
| Principal investigator 1 | COLOPLAST CORP | $1,359.45 | 03/13/2025 | Non-covered Recipient Entity Centers for Advanced Urology LLP | INTIBIA | No dispute reported | 06/30/2026 | 1226927368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $107.00 | 03/13/2025 | Non-covered Recipient Entity Urologic Consultants Of Southeastern Pennsylvania | A Phase 3 Randomized Placebo controlled Double blind Study of Apalutamide Plus Androgen Deprivation Therapy ADT Versus ADT in Subjects With Metastatic Hormone sensitive Prostate Cancer mHSPC | No dispute reported | 06/30/2026 | 1175264345 |
| Principal investigator 1 | Merck Sharp & Dohme LLC | $19,289.40 | 03/12/2025 | Non-covered Recipient Entity MidLantic urology | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer NMIBC Unresponsive to Bacillus Calmett | No dispute reported | 06/30/2026 | 1232924972 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,290.00 | 03/10/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus CalmetteGurin (BCG) in Participants with BCG-nave High-Risk Non-Muscle Invasive Bladder Canc | No dispute reported | 06/30/2026 | 1175378751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $12,502.00 | 03/10/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379006 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 03/06/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658821 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,354.00 | 03/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Controlled, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients with PSMA-PET-Positive Hormone-Sensitive Prostate Cancer, with an Observational Fo | No dispute reported | 06/30/2026 | 1175378869 |
| Principal investigator 1 | MEDIVATION LLC. | $240.50 | 03/03/2025 | Non-covered Recipient Entity THE CENTERS FOR ADVANCED UROLOGY LLC | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS LEUPROLIDE IN MEN WITH HIGHRISK NONMETASTATIC PROSTATE CANCER PROGRESSING AFTER DEFINITIVE THERAPY | No dispute reported | 06/30/2026 | 1228786080 |
| Principal investigator 1 | Dendreon Pharmaceuticals LLC | $4,300.00 | 02/26/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY | PROVONE STUDY | No dispute reported | 06/30/2026 | 1247891734 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,750.00 | 02/25/2025 | Non-covered Recipient Entity Midlantic Urology | BAY 1841788, A roll-over study to provide continued treatment with darolutamide in subjects who were entered in darolutamide studies | No dispute reported | 06/30/2026 | 1225406422 |
| Principal investigator 1 | Janssen Research & Development, LLC | $933.00 | 02/24/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378801 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,721.00 | 02/21/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264458 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 02/18/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658819 |
| Principal investigator 1 | Janssen Research & Development, LLC | $23,253.00 | 02/17/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378954 |
| Principal investigator 1 | Janssen Research & Development, LLC | $42,268.00 | 02/17/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175379126 |
| Principal investigator 1 | Janssen Research & Development, LLC | $35,730.00 | 02/17/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175379171 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 02/14/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658817 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,918.00 | 02/13/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4) | No dispute reported | 06/30/2026 | 1175264579 |
| Principal investigator 1 | Janssen Research & Development, LLC | $24,914.00 | 02/10/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) | No dispute reported | 06/30/2026 | 1175379058 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $2,000.00 | 02/07/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227681228 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $10,000.00 | 02/07/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227681604 |
| Principal investigator 1 | IRONWOOD PHARMACEUTICALS, INC | $500.00 | 02/07/2025 | Non-covered Recipient Entity Midlantic Bala Cynwyd Urology Research | C3300-201 | No dispute reported | 06/30/2026 | 1227681957 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 02/06/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658815 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,156.85 | 02/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy | No dispute reported | 06/30/2026 | 1175378891 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,542.00 | 02/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy | No dispute reported | 06/30/2026 | 1175378969 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,543.00 | 02/03/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLC | A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator's Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Gurin (BCG) and Recurred with High-risk Non-musc | No dispute reported | 06/30/2026 | 1175379026 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 01/31/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658813 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 01/31/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658885 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $189,159.75 | 01/29/2025 | Non-covered Recipient Entity MIDLANTIC UROLOGY LLC | a phase 3b,open label,single arm,multi center,US study of bacillus calmette guerin bcg administered in combination with durvalumab in adult bcg naive,high risk non muscle invasive bladder cancer participants patapsco | No dispute reported | 06/30/2026 | 1185543190 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $352.97 | 01/29/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403489 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $352.97 | 01/29/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406994 |
| Principal investigator 1 | Sumitomo Pharma America, Inc. | $1,818.00 | 01/29/2025 | Non-covered Recipient Entity CENTERS FOR ADVANCED UROLOGY LLP DBA MIDLANTIC | RELUGOLIX VERSUS LEUPROLIDE IN PATIENTS WITH PROSTATE CANCER: A RANDOMIZED, OPEN-LABEL STUDY TO ASSESS MAJOR ADVERSE CARDIOVASCULAR EVENTS (REPLACE-CV) | No dispute reported | 06/30/2026 | 1176624936 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,526.00 | 01/28/2025 | Non-covered Recipient Entity Centers For Advanced Uro Llc DBA Midlantic Uro | A Study of TAR200 in Combination With Cetrelimab TAR200 Alone or Cetrelimab Alone in Participants With Non Muscle Invasive Bladder Cancer NMIBC Unresponsive to Intravesical Bacillus Calmette Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy | No dispute reported | 06/30/2026 | 1175264450 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 01/23/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658811 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 01/21/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658809 |
| Principal investigator 1 | Blue Earth Diagnostics | $5,065.80 | 01/17/2025 | Non-covered Recipient Entity MidLantic Urology | Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management | No dispute reported | 06/30/2026 | 1252658807 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403209 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225403211 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $7,344.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404167 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $5,358.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225404439 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405182 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405592 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405598 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405600 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225405714 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406026 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $396.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406200 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406246 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $6,018.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406430 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,980.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406432 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406434 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406436 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $500.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225406770 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $198.00 | 01/03/2025 | Non-covered Recipient Entity Regents Of The University Of California At Irvine Attn: Kenneth J Chang | BAY 1841788, Open-label study of Androgen Receptor Inhibition with dArolutamide plus Androgen Deprivation Therapy (ADT) Versus ADT in men with Metastatic Hormone-Sensitive Prostate Cancer not planned for chemotherapy Using an External Control Arm ARASEC | No dispute reported | 06/30/2026 | 1225407068 |